Skip to main content
Premium Trial:

Request an Annual Quote

Natera Raises $54.6M to Support Expansion of Panorama Test

NEW YORK (GenomeWeb News) – Noninvasive prenatal test developer Natera has completed a $54.6 million financing round to support its expansion and the rollout of its sequencing-based fetal aneuploidy test called Panorama.

Two new investors, OrbiMed Advisors and Harmony Partners, and other new undisclosed investors joined the company's existing investors, Claremont Creek Ventures, Lightspeed Venture Partners, Founders Fund, and Sequoia Capital.

"This new financing will support the expansion of our lab and our team to meet the rapidly increasing demand," CEO Matthew Rabinowitz said in a statement. "We have successfully launched Panorama, and with our partners are seeing strong demand from expecting mothers who want reliable, early information about their fetus."

Additionally, in a study published today in Prenatal Diagnosis, the company said its test demonstrated 100 percent sensitivity and specificity in calling fetal aneuploidies from 242 samples.

Overall, from all of its studies, the Panorama test has demonstrated greater than 99 percent sensitivity for trisomy 21, 18, and 13; 92 percent sensitivity for monosomy X; and a specificity of 100 percent with no false positives for all indications.

Rabinowitz said in the statement that the company will continue to "investigate new applications" for its technology.

Natera has so far inked deals with Quest, Bio-Reference Laboratories, and Arup Laboratories to offer its test.

The firm competes with several other companies in the noninvasive prenatal testing space including Sequenom, Illumina's Verinata Health, and Ariosa Diagnostics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.